CIK 0001815442
- Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 812992166
- Phone
- +1 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- 4 Planned sale Director sold 5,000 shares at an average $89.76 ($448,823)
- 4 Planned sale Chief Executive Officer sold 100,000 shares at $89.17 ($8,917,000)
- 4 Planned sale Chief Medical Officer sold 49,307 shares at an average $88.67 ($4,371,833)
- 4 Planned sale Chief Executive Officer sold 30,000 shares at an average $60.99 ($1,829,737)
- 4 Planned sale Chief Medical Officer sold 59,576 shares at an average $61.42 ($3,659,254)
- 4 Planned sale Chief Medical Officer sold 3,114 shares at $60.00 ($186,840)
- 4 Planned sale Director sold 5,000 shares at $59.19 ($295,949)
- 4 Planned sale Chief Financial Officer sold 79,220 shares at $50.00 ($3,961,380)
- 4 Planned sale Chief Executive Officer sold 30,000 shares at $49.00 ($1,470,000)
- 4 Grant or award Chief Legal Officer acquired 52,500 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 317,167 shares at $44.00 ($13,955,348)
- 4 Open-market buy Director bought 655,500 shares at $44.00 ($28,842,000)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 4 of 15 · 296 filings